Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 36.36 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $10.267 million which missed the analyst consensus estimate of $16.493 million by 37.75 percent.